We are live on ! Find out more
MREO

Mereo BioPharma
MREO

47 hedge funds and large institutions have $205M invested in Mereo BioPharma in 2020 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

438% more capital invested

Capital invested by funds: $38.1M → $205M (+$167M)

333% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 6

68% more funds holding

Funds holding: 28 → 47 (+19)

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

8.56% more ownership

Funds ownership: 4.57% → 13.13% (+8.6%)

Holders
47
Holders Change
+19
Holders Change %
+67.86%
% of All Funds
0.83%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
26
Increased
8
Reduced
6
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$15.1M
2
Citadel Advisors
Citadel Advisors
Florida
+$10.3M
3
SCM
Suvretta Capital Management
New York
+$6.89M
4
BC
Boxer Capital
California
+$5.5M
5
Alkeon Capital Management
Alkeon Capital Management
New York
+$4.85M

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$5.01M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$745K
3
MWNA
Marshall Wace North America
New York
-$467K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$301K
5
JG
Jefferies Group
New York
-$236K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$49.5M – – –
BC
2
Boxer Capital
California
$22.3M +$5.5M +2,197,024 +55%
BBA
3
Baker Bros. Advisors
New York
$21.6M +$15.1M +6,030,293 New
VC
4
Vivo Capital
California
$15.1M -$5.01M -2,000,000 -32%
Citadel Advisors
5
Citadel Advisors
Florida
$14.7M +$10.3M +4,097,346 +22,626%
HA
6
HHLR Advisors
Cayman Islands
$10.7M +$3.45M +1,377,936 +86%
SCM
7
Suvretta Capital Management
New York
$9.84M +$6.89M +2,748,999 New
Alkeon Capital Management
8
Alkeon Capital Management
New York
$6.93M +$4.85M +1,935,600 New
CC
9
Commodore Capital
New York
$6.64M +$4.64M +1,854,278 New
RCMNY
10
Rubric Capital Management (New York)
New York
$6.63M +$4.64M +1,853,417 New
Holocene Advisors
11
Holocene Advisors
New York
$6.14M +$4.3M +1,714,932 New
Schroder Investment Management Group
12
Schroder Investment Management Group
United Kingdom
$5.62M +$3.93M +1,569,174 New
SSA
13
Schonfeld Strategic Advisors
New York
$4.14M +$2.04M +814,805 +237%
Janus Henderson Group
14
Janus Henderson Group
United Kingdom
$4M +$2.82M +1,124,678 New
ACM
15
Asymmetry Capital Management
California
$2.65M +$1.85M +739,812 New
TLP
16
Tri Locum Partners
New York
$2.61M +$1.83M +728,710 New
DCM
17
DAFNA Capital Management
California
$2.39M +$1.17M +468,723 +235%
AAA
18
Affinity Asset Advisors
New York
$2.24M +$1.57M +625,000 New
Primecap Management
19
Primecap Management
California
$1.75M – – –
MIM
20
Monashee Investment Management
Massachusetts
$1.65M +$1.16M +461,639 New
JGC
21
J. Goldman & Co
New York
$1.65M +$41.4K +16,534 +4%
Renaissance Technologies
22
Renaissance Technologies
New York
$1.29M +$847K +338,000 +1,594%
SCM
23
Silverarc Capital Management
Massachusetts
$1M +$701K +280,000 New
DMPV
24
Delphi Management Partners VIII
California
$919K +$643K +256,734 New
SC
25
Shay Capital
New York
$594K +$415K +165,811 New
1
2 3

MREO Hedge Fund Activity: Q4 2020 in Review

47 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q4 2020, worth a combined $205M — up 438% from $38.1M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new MREO positions and 6 closed out — a net gain of 20 holders — while 8 added to existing stakes and 6 trimmed.

The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $15.1M. The largest seller was Vivo Capital, cutting an estimated $5.01M.

  • 47 institutional investors held Mereo BioPharma (MREO) as of Q4 2020, up from 28 in Q3 2020.
  • Funds reported $205M of Mereo BioPharma stock for Q4 2020, up 438% quarter-over-quarter.
  • 26 funds opened new Mereo BioPharma positions in Q4 2020 and 6 closed out, a net change of +20 holders.
  • The largest Mereo BioPharma buyer in Q4 2020 was Baker Bros. Advisors, an estimated $15.1M added.
  • The largest Mereo BioPharma seller in Q4 2020 was Vivo Capital, an estimated $5.01M sold.

Based on aggregated 13F filings for Q4 2020.